Tetranectin demonstrates roles in cardiac fibrosis and inflammation following myocardial injury, and plasma tetranectin levels may serve as a potential biomarker to differentiate between patients presenting with breathlessness who have normal heart function versus those with acute heart failure.
Tetranectin expression was investigated in human cardiac fibroblasts under both normoxic and hypoxic conditions to mimic ischaemia within the myocardium.
In vivo assessment of myocardial repair was conducted using wild type and tetranectin gene knockout mice undergoing experimental myocardial infarction.
Plasma tetranectin levels were assessed as a potential biomarker to distinguish between a breathless non-heart failure population and those with acute heart failure.
Tetranectin was found to have a relationship with fibrosis and inflammation following myocardial injury.
Plasma tetranectin demonstrated potential as a biomarker for differentiating patients presenting with breathlessness with normal heart function from those with acute heart failure.
This research suggests that a protein called tetranectin, found in blood plasma, plays a role in heart disease—specifically in the scarring (fibrosis) and inflammation that occurs after a heart attack. The researchers studied this protein using three approaches: growing human heart cells in low-oxygen conditions to mimic a heart attack environment, using genetically modified mice that lack the tetranectin gene to see how the heart heals after a heart attack, and measuring tetranectin levels in the blood of patients who were short of breath, comparing those with normal heart function to those with acute heart failure. This research suggests that tetranectin is involved in how the heart responds to injury and remodels itself afterward. By comparing mice with and without the tetranectin gene after experimental heart attacks, the study aimed to reveal whether tetranectin helps or harms the heart's recovery process. Additionally, the blood-based measurements suggest that tetranectin levels in plasma could potentially help doctors distinguish between patients whose breathlessness is caused by heart failure versus other causes—a clinically important distinction that currently relies on tests like NT-proBNP. This matters because identifying patients with acute heart failure quickly and accurately is critical for appropriate treatment, and current biomarkers are not always sufficient. This research suggests tetranectin could serve as an additional or alternative blood test to help with this diagnosis, while also shedding light on the biological mechanisms behind cardiac scarring that contributes to heart failure progression.
Bhandari A, Edgar K, Glezeva N, Gallagher J, Rammos A, Ledwidge M, et al.. (2026). Investigating the Role of Tetranectin in Ischaemic Heart Disease and Heart Failure.. The Ulster medical journal. https://doi.org/10.1016/j.cvdhj.2022.09.002